Stephens downgraded shares of Trinity Biotech PLC (NASDAQ:TRIB) from an overweight rating to an equal weight rating in a research note released on Wednesday morning.

Separately, Zacks Investment Research raised shares of Trinity Biotech PLC from a sell rating to a hold rating in a report on Saturday, August 20th.

Shares of Trinity Biotech PLC (NASDAQ:TRIB) traded up 2.9937% on Wednesday, reaching $6.4989. 526,082 shares of the company’s stock were exchanged. The stock has a market cap of $149.58 million, a P/E ratio of 27.6549 and a beta of 0.97. The company’s 50 day moving average price is $12.53 and its 200-day moving average price is $11.76. Trinity Biotech PLC has a 52-week low of $5.76 and a 52-week high of $13.68.

Trinity Biotech PLC (NASDAQ:TRIB) last posted its earnings results on Thursday, July 21st. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.03. The firm earned $26.30 million during the quarter, compared to analysts’ expectations of $24.30 million. Trinity Biotech PLC had a net margin of 15.77% and a return on equity of 3.03%. Equities analysts forecast that Trinity Biotech PLC will post $0.14 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of TRIB. Paradice Investment Management LLC raised its position in shares of Trinity Biotech PLC by 13.3% in the second quarter. Paradice Investment Management LLC now owns 1,626,496 shares of the company’s stock worth $18,444,000 after buying an additional 190,772 shares during the period. Royce & Associates LP raised its position in shares of Trinity Biotech PLC by 13.7% in the first quarter. Royce & Associates LP now owns 799,098 shares of the company’s stock worth $9,317,000 after buying an additional 96,500 shares during the period. Emerald Acquisition Ltd. acquired a new position in shares of Trinity Biotech PLC during the second quarter worth about $5,109,000. Adirondack Research & Management Inc. raised its position in shares of Trinity Biotech PLC by 1.3% in the first quarter. Adirondack Research & Management Inc. now owns 415,353 shares of the company’s stock worth $4,843,000 after buying an additional 5,466 shares during the period. Finally, Kimelman & Baird LLC raised its position in shares of Trinity Biotech PLC by 0.6% in the first quarter. Kimelman & Baird LLC now owns 109,367 shares of the company’s stock worth $1,275,000 after buying an additional 675 shares during the period. Institutional investors and hedge funds own 71.14% of the company’s stock.

About Trinity Biotech PLC

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

5 Day Chart for NASDAQ:TRIB

Receive News & Stock Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related stocks with our FREE daily email newsletter.